(Report ID: 54031) Many drug interactions and side effects can not be detected until the drugs have been used by millions of people, and for a long time. Large, long-term drug safety studies are ideal to discover these real-world drug outcomes. For the first time, eHealthMe enables health professionals and patients to conduct these studies for their drugs. Click here to check your drugs now, in a whole new way. As of Nov, 21, 2008, eHealthMe analyzes 10,180,629 drug interactions and side effects of 21,667 FDA-approved drugs from 1977 to the present. Results on Nov, 21, 2008: 3 relevant incidents
Note:
- The incidents can not include all actual occurrences
- Data of 2008 is not complete
DISCLAIMER: All adverse drug reaction material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only, and has not been supported by scientific studies or clinical trials unless otherwise stated. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk. Basic information:
| Report ID | Date of submission | Patient age | Patient gender |
| 54031 | Feb, 17, 2006 | 47 | Male |
List of drugs the patient takes:
| Drug |
Colestipol Hcl |
Rebetol |
List of drug interactions, adverse side effects / events the patient has:
| Name |
Alanine Aminotransferase Increased |
Blood Bilirubin Increased |
Liver Disorder |
Nausea |
Platelet Count Decreased |
Vomiting |
White Blood Cell Count Increased |
Results from eHealthMe: 3 relevent incidents1) Comparison with the patient's adverse outcomes:
| Name | Count (% of total reports) |
Alanine Aminotransferase Increased | 1 (33.33%) |
Blood Bilirubin Increased | 1 (33.33%) |
Liver Disorder | 1 (33.33%) |
Nausea | 2 (66.67%) |
Platelet Count Decreased | 1 (33.33%) |
Vomiting | 1 (33.33%) |
White Blood Cell Count Increased | 1 (33.33%) |
2) Top drug interactions, adverse side effects reported for the past 12 months:
3) Top co-used drugs drugs reported for the past 12 months:
4) Top drug interactions, adverse side effects reported of all time:Death: 0 Cancer: 0
| Name | Count (% of total reports) |
1 | Nausea | 2 (66.67%) |
2 | Dehydration | 1 (33.33%) |
3 | Chest Pain | 1 (33.33%) |
4 | Dry Throat | 1 (33.33%) |
5 | Haemolytic Anaemia Nos | 1 (33.33%) |
6 | Vomiting Nos | 1 (33.33%) |
7 | Pharyngolaryngeal Pain | 1 (33.33%) |
8 | Hyponatraemia | 1 (33.33%) |
9 | White Blood Cell Count Increased | 1 (33.33%) |
10 | Platelet Count Decreased | 1 (33.33%) |
5) Top co-used drugs drugs reported of all time:
| Name | Count |
1 | Peg-intron | 2 |
2 | Quinidine Hcl | 1 |
3 | Alprazolam | 1 |
4 | Prilosec | 1 |
5 | Digoxin | 1 |
6 | Colestid | 1 |
7 | Phenergan | 1 |
8 | Aspirin | 1 |
9 | Cardizem | 1 |
10 | Hydrochlorothiazide | 1 |
Want to have a risk analysis report like this for your drugs? Click here. ADVERTISEMENT
----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- Recent drug risk analysis reports:
Dipyridamole (Actavis Totowa) - 75MG for Stroke (Nov, 21, 2008)
|
Prozac (Lilly) - EQ 20MG BASE for Depression (Nov, 21, 2008)
|
Cymbalta (Eli Lilly) - 60MG for Depression (Nov, 20, 2008)
|
Fluconazole (Dr Reddys Labs Inc) - 15... for Candidiasis (Nov, 20, 2008)
|
Yaz (Bayer Hlthcare) - 3MG; 0.02MG for Birth Control (Nov, 20, 2008)
|
Astelin (Meda Pharms) - EQ 0.125MG BA... for Pet Allergies (Nov, 20, 2008)
|
Cyclobenzaprine Hydrochloride (Actavi... for Lower Back Pain (Nov, 20, 2008)
|
Prozac (Lilly) - EQ 40MG BASE for Anxiety (Nov, 20, 2008)
|
Norvasc (Pfizer) - EQ 5MG BASE for BLOOD PRESSURE (Nov, 20, 2008)
|
Bentyl (Axcan) - 20MG for Pain - Abdomen (Nov, 20, 2008)
|
|
|
|
 |
|
How to use the report?
Bring a copy of this report to a doctor's appointment to ensure drug risks are fully discussed and understood, in the process of risk and benefit assessment.
|
 |
|
ADVERTISEMENT
|
|